Literature DB >> 19242611

The angiopoietin/Tie2 axis mediates malignant pleural effusion formation.

Charalampos Moschos1, Ioannis Psallidas, Androniki Kollintza, Sophia Karabela, Andreas Papapetropoulos, Spyros Papiris, Richard W Light, Charis Roussos, Georgios T Stathopoulos, Ioannis Kalomenidis.   

Abstract

PURPOSE: Angiopoietins and their receptor, Tie2, participate in angiogenesis, regulation of vascular permeability, and inflammation, all central to the pathogenesis of malignant pleural effusions (MPEs). In the present study, we aimed to examine the role of the angiopoietin/Tie2 axis in MPE pathogenesis. EXPERIMENTAL
DESIGN: MPE was induced by intrapleural injection of murine adenocarcinoma cells in C57BL/6 mice. Animals were given twice-weekly intraperitoneal injections of 40 mg/kg MuTekdeltaFc or vehicle. MuTekdeltaFc is a soluble Tie2 (sTie2) receptor that binds murine angiopoietins thereby disrupting their interaction with Tie2 receptors expressed on tissues. Animals were killed on day 14.
RESULTS: Angiopoietin/Tie2 axis blockade significantly reduced pleural fluid volume and pleural tumor foci. The mean +/- SEM pleural fluid volumes were 617 +/- 48 microl and 316 +/- 62 microl for the control and treated groups, respectively (P = .001), whereas the mean +/- SEM tumor foci were 7.3 +/- 1.0 and 3.0 +/- 0.52 for the control and treated groups, respectively (P = .001). In addition, tumor-associated cachexia, tumor angiogenesis, pleural vascular permeability, recruitment of inflammatory cells to the pleural cavity, and local elaboration of vascular endothelial growth factor and interleukin 6 were also downregulated, and tumor cell apoptosis was induced in animals treated with the inhibitor.
CONCLUSIONS: Our results indicate that the angiopoietin/Tie2 axis is an important component of MPE pathogenesis. Further studies are required to determine whether therapeutic interventions targeting this pathway could be beneficial for patients with MPE.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19242611      PMCID: PMC2647732          DOI: 10.1593/neo.81480

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  39 in total

1.  Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth.

Authors:  P Lin; P Polverini; M Dewhirst; S Shan; P S Rao; K Peters
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

2.  Angiopoietins can directly activate endothelial cells and neutrophils to promote proinflammatory responses.

Authors:  Caroline Lemieux; Ricardo Maliba; Judith Favier; Jean-François Théorêt; Yahye Merhi; Martin G Sirois
Journal:  Blood       Date:  2004-10-21       Impact factor: 22.113

3.  Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage.

Authors:  Fiorentina Roviezzo; Stelios Tsigkos; Anastasia Kotanidou; Mariarosaria Bucci; Vincenzo Brancaleone; Giuseppe Cirino; Andreas Papapetropoulos
Journal:  J Pharmacol Exp Ther       Date:  2005-05-03       Impact factor: 4.030

4.  Angiopoietin affects neutrophil migration.

Authors:  Daniel H Sturn; Clemens Feistritzer; Birgit A Mosheimer; Angela Djanani; Klaudija Bijuklic; Josef R Patsch; Christian J Wiedermann
Journal:  Microcirculation       Date:  2005 Jul-Aug       Impact factor: 2.628

5.  Expression and regulation of murine macrophage angiopoietin-2.

Authors:  Neil E Hubbard; Debora Lim; Mithia Mukutmoni; Ann Cai; Kent L Erickson
Journal:  Cell Immunol       Date:  2005-04       Impact factor: 4.868

6.  Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway.

Authors:  G Siemeister; M Schirner; K Weindel; P Reusch; A Menrad; D Marmé; G Martiny-Baron
Journal:  Cancer Res       Date:  1999-07-01       Impact factor: 12.701

7.  Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Comparison with flow cytometric analysis.

Authors:  R L Garcia; M D Coltrera; A M Gown
Journal:  Am J Pathol       Date:  1989-04       Impact factor: 4.307

8.  Comparative morphometric study of tumor vasculature in human squamous cell carcinomas and their xenotransplants in athymic nude mice.

Authors:  S Lauk; A Zietman; S Skates; R Fabian; H D Suit
Journal:  Cancer Res       Date:  1989-08-15       Impact factor: 12.701

9.  Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2.

Authors:  P Lin; J A Buxton; A Acheson; C Radziejewski; P C Maisonpierre; G D Yancopoulos; K M Channon; L P Hale; M W Dewhirst; S E George; K G Peters
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

10.  Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.

Authors:  Michele De Palma; Mary Anna Venneri; Rossella Galli; Lucia Sergi Sergi; Letterio S Politi; Maurilio Sampaolesi; Luigi Naldini
Journal:  Cancer Cell       Date:  2005-09       Impact factor: 31.743

View more
  13 in total

1.  The interconnectedness of cancer cell signaling.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

Review 2.  Switching off malignant pleural effusion formation-fantasy or future?

Authors:  Magda Spella; Anastasios D Giannou; Georgios T Stathopoulos
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

3.  Angiopoietins as biomarkers of disease severity and bacterial burden in pulmonary tuberculosis.

Authors:  N P Kumar; B Velayutham; D Nair; S Babu
Journal:  Int J Tuberc Lung Dis       Date:  2017-01-01       Impact factor: 2.373

4.  A Case of Massive Cerebral Arterial Air Embolism Induced by Artificial Pneumothorax and Its Analysis.

Authors:  Xiao-Hua Gou; Wei Yang; Yan-Li Zhang; Ya Li; Xin Wu
Journal:  Med Princ Pract       Date:  2018-12-19       Impact factor: 1.927

5.  Dinosaurs and ancient civilizations: reflections on the treatment of cancer.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

Review 6.  Malignant pleural effusion: tumor-host interactions unleashed.

Authors:  Georgios T Stathopoulos; Ioannis Kalomenidis
Journal:  Am J Respir Crit Care Med       Date:  2012-05-31       Impact factor: 21.405

7.  Effect of Endostar combined with angiopoietin-2 inhibitor on malignant pleural effusion in mice.

Authors:  Shen-Cun Fang; Hai-Tao Zhang; Hui-Di Hu; Cai-Ying Wang; Ying-Ming Zhang
Journal:  Med Oncol       Date:  2014-12-06       Impact factor: 3.064

8.  The War on Cancer rages on.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

9.  Upregulation of tissue factor by activated Stat3 contributes to malignant pleural effusion generation via enhancing tumor metastasis and vascular permeability in lung adenocarcinoma.

Authors:  Hsuan-Heng Yeh; Wen-Tsan Chang; Kuang-Chu Lu; Wu-Wei Lai; Hsiao-Sheng Liu; Wu-Chou Su
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240

10.  Beneficial impact of CCL2 and CCL12 neutralization on experimental malignant pleural effusion.

Authors:  Antonia Marazioti; Chrysoula A Kairi; Magda Spella; Anastasios D Giannou; Sophia Magkouta; Ioanna Giopanou; Vassilios Papaleonidopoulos; Ioannis Kalomenidis; Linda A Snyder; Dimitrios Kardamakis; Georgios T Stathopoulos
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.